Next Article in Journal
Crosstalk of PmCBFs and PmDAMs Based on the Changes of Phytohormones under Seasonal Cold Stress in the Stem of Prunus mume
Next Article in Special Issue
Poly-N-Acetyllactosamine Neo-Glycoproteins as Nanomolar Ligands of Human Galectin-3: Binding Kinetics and Modeling
Previous Article in Journal
Heat Shock Proteins and Autophagy Pathways in Neuroprotection: From Molecular Bases to Pharmacological Interventions
Previous Article in Special Issue
Galectin Targeted Therapy in Oncology: Current Knowledge and Perspectives
Article Menu
Issue 1 (January) cover image

Export Article

Open AccessArticle
Int. J. Mol. Sci. 2018, 19(1), 323; https://doi.org/10.3390/ijms19010323

Overall Survival of Ovarian Cancer Patients Is Determined by Expression of Galectins-8 and -9

1
LMU Munich, University Hospital, Department of Obstetrics and Gynecology, Maistrasse 11, 80337 Munich, Germany
2
LMU Munich, Department of Pathology, Ludwig Maximilians University of Munich, Thalkirchner Str. 142, 80337 Munich, Germany
*
Author to whom correspondence should be addressed.
Received: 28 November 2017 / Revised: 16 January 2018 / Accepted: 18 January 2018 / Published: 22 January 2018
(This article belongs to the Special Issue Galectins in Cancer and Translational Medicine)
View Full-Text   |   Download PDF [1265 KB, uploaded 2 February 2018]   |  

Abstract

The evaluation of new prognostic factors that can be targeted in ovarian cancer diagnosis and therapy is of the utmost importance. Galectins are a family of carbohydrate binding proteins with various implications in cancer biology. In this study, the presence of galectin (Gal)-8 and -9 was investigated in 156 ovarian cancer samples using immunohistochemistry (IHC). Staining was evaluated using semi-quantitative immunoreactivity (IR) scores and correlated to clinical and pathological data. Different types of galectin expression were compared with respect to disease-free survival (DFS) and overall survival (OS). Gal-8 served as a new positive prognostic factor for the OS and DFS of ovarian cancer patients. Gal-9 expression determined the DFS and OS of ovarian cancer patients in two opposing ways—moderate Gal-9 expression was correlated with a reduced outcome as compared to Gal-9 negative cases, while patients with high Gal-9 expression showed the best outcome. View Full-Text
Keywords: galectin-8; galectin-9; immunochemistry; ovarian cancer; prognostic factor; disease-free survival; overall survival galectin-8; galectin-9; immunochemistry; ovarian cancer; prognostic factor; disease-free survival; overall survival
Figures

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Schulz, H.; Kuhn, C.; Hofmann, S.; Mayr, D.; Mahner, S.; Jeschke, U.; Schmoeckel, E. Overall Survival of Ovarian Cancer Patients Is Determined by Expression of Galectins-8 and -9. Int. J. Mol. Sci. 2018, 19, 323.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top